Dopamine transporter in obesity: a meta-analysis

1. INTRODUCTION

Obesity rate has nearly tripled worldwide since 1975, and has become one of the major public health threats(2), as obesity is known to be a risk factor for malignancies of colon (2), pancreas (3), thyroid (4), liver (5), and uterus (6) as well as for cardiovascular diseases (7). Obesity arises from energy intake that chronically exceeds the energy expenditure (8). This excessive eating behavior as known as overeating has phenomenological similarities with excessive drug use in addiction (9). In this regard, researchers have focused on how the brain regulates eating behavior, and how obesity affects the brain (10, 11). Among the neurotransmitters synthesized in the brain, dopamine plays a major role in eating behavior as well as the executive function, motor control, and motivation (12-14). The role of the dopamine system in obesity, and eating behavior has been investigated with the help of neuroimaging using radiopharmaceuticals, as there is no direct method to measure dopamine levels in the human brain (11). Especially, dopamine receptor (DR) has been discussed widely with regard to obesity. However, the association between obesity and DR remains unclear due to the lack of agreement between the previous studies (15-18), probably due to the characteristics of the radiopharmaceuticals, or the study design.

Dopamine transporter (DAT) is a transmembrane protein that drives reuptake of extracellular dopamine into presynaptic neurons (19). Also, DAT is a major target for various pharmacologically active drugs (19). However, DAT has not been investigated widely in the view of obesity, in addition, the association of DAT with obesity showed the inconsistent results. In the study by Chen et al., DAT availability measured from ^99mTc-TRODAT single-photon emission computed tomography (SPECT) was negatively correlated with body mass index (BMI) (20). However, other studies did not find the significant association between DAT availability and BMI (1, 21, 22). Therefore, we performed a meta-analysis to assess the association between DAT availability measured with radiopharmaceuticals, and obesity.

2. MATERIALS AND METHODS

3. RESULTS

3.1. Study Characteristics

The electronic search identified 423 articles. Conference abstracts (n=183), animal studies (n=50), non-English studies (21), and studies that did not meet the inclusion criteria after screening the title or abstract (n=159) were excluded. After reviewing the full text of 10 articles, 5 studies including 421 subjects were eligible for inclusion in this study (1, 20, 22-24) (Figure 1). Two studies with ¹²³I-FP-CIT (22, 24), one with ^99mTc-TRODAT (20), one with ¹²³I-PE21 (1), and one with ¹⁸F-FP-CIT (23) were included. DAT availability was extracted from figures in 3 studies (1, 20, 22). In 3 studies that extracted data from figures, BMI and the corresponding DAT availability were extracted from 50 of 50 subjects (20), 114 of 123 subjects (22), and 33 of 33 subjects (1). The calculated DAT availability was downloaded from website of the shared database (Parkinson’s Progression Markers Initiative, PPMI; http://www.ppmi-info.org/) in one study (24). Previously published data from our group was extracted in one study (23). Three studies included the subjects from each institution (1, 20, 23), and the study by van de Giessen et al. (22) analyzed the data of European databases of [123I]FP-CIT SPECT scans of healthy controls (ENC-DAT; http://earl.eanm.org/cms/website.php?id=/en/projects/enc-dat.htm) project with 13 sites from 10 European countries without overlaps with PPMI database (24). Table 1 summarizes the study characteristics.

View this table:

• View inline
• View popup
• Download powerpoint

Table 1.

Studies included in a meta-analysis

• Download figure
• Open in new tab

Figure 1.

Flowchart

3.2. Association of DAT availability or DAT ratio with BMI

Data of 2 studies with ¹²³I-FP-CIT (22, 24) were plotted for each ROI (caudate nucleus, putamen) (Figure 2). DAT availabilities from ENC-DAT project (22) were higher than those from PPMI database (24) both for caudate nucleus (p<0.0001), and putamen (p<0.0001) (Figure 2). As there might be the inter-study variability, we calculated DAT ratio, after dividing DAT availabilities of subjects with overweight/obese BMI with mean DAT availabilities of subjects with normal BMI. Linear regression between BMI, and DAT ratio was not significant for both caudate nucleus (p=0.4730), and putamen (p=0.5921). Spline curves of DAT ratio from caudate nucleus, and putamen did not increase or decrease as BMI increases (Figure 3). In the study by Chen et al. with ^99mTc-TRODAT, 14 subjects had BMI of 25kg/m² or more (20). DAT ratio was lower than 1 in subjects with BMI of 25kg/m² or more except for 1 subject, with the trend of decrease as BMI increases (Figure 4A). In the study by Thomsen et al. with ¹²³I-PE21, 21 subjects had BMI of 25kg/m² or more (1). Spline curves of DAT ratio from striatum did not increase or decrease as BMI increases (Figure 4B). As there were 6 subjects with BMI of 25kg/m² or more in the study by Pak et al., curve fitting for DAT ratio, and BMI could not be done (23).

• Download figure
• Open in new tab

Figure 2.

Scatter plots of DAT availability and BMI; A. Caudate nucleus; B. Putamen

• Download figure
• Open in new tab

Figure 3.

Scatter plots and spline curves of DAT ratio and BMI; A. Caudate nucleus; B. Putamen

• Download figure
• Open in new tab

Figure 4.

Scatter plots of DAT ratio, and BMI; A. ^99mTc-TRODAT; B. ¹²³I-PE21

4. DISCUSSION

In this study, we have shown that DAT availability of subjects with overweight/obesity was not different from those with normal BMI. Although DAT has not been discussed widely with regard to obesity, 5 studies of 421 subjects could be included in this study. Except for one study by Chen et al.(20), 4 studies have shown no significant association between DAT availability and BMI (1, 21-23). Chen et al. used ^99mTc-TRODAT SPECT to measure DAT availability, and showed the negative correlation between DAT availability and BMI (20). ^99mTc-TRODAT is a radiopharmaceutical based on a tropane structure, showing similar diagnostic performance with ¹²³I-FP-CIT to detect Parkinsonism (25). However, there might be the difference of binding capacity of radiopharmaceuticals in healthy subjects. Among 3 other studies that included in this meta-analysis, 2 studies with ¹²³I-FP-CIT (22, 24), and 1 study with ¹²³I-PE21 (1) did not show the significant correlation between DAT availability and BMI. In a previous study by Ziebell et al.(26), ¹²³I-FP-CIT and ¹²³I-PE21 showed the same target-to-background ratios, however, ¹²³I-FP-CIT gave rise to 3-fold higher counting rates per injected dose. From 2 studies with ¹²³I-FP-CIT, we extracted the data from the figure using the software (22), or the website of PPMI (24). In both of 2 studies, DAT availability was measured from striatal regions of caudate nucleus, and putamen (22, 24). However, as shown in figure 2, systematic difference between 2 studies might exist due to study design such as image acquisition, study population. Therefore, we plotted the data of DAT ratio of overweight/obese subjects to investigate the DAT availability adjusted for inter-study variability.. In the study by Thomsen et al.(1), ¹²³I-PE21 also did not change significantly according to BMI. However, the numbers of overweight/obese subjects included in studies of Chen et al. with ^99mTc-TRODAT (20), and Thomsen et al.(1) with ¹²³I-PE21 were small.

Dopamine plays a major role in modulating motivation and in reward processing (27). There are two major hypotheses regarding the role of dopamine. The first hypothesis, dopamine hyperresponsiveness, explains that there is a hypersensitivity to rewards which is related to an increased behavioural salience towards food leading to the excessive intake of highly palatable foods(28, 29). The second hypothesis, reward deficiency syndrome, states that subjects who are insensitive to rewards overeat to increase their endogenous dopamine levels (28, 29). Therefore, a nonlinear relationship of an inverted parabola has been proposed between the DR and BMI based on previous study (30). In mild obesity, the change in DR is not significant. However, with the onset of moderate obesity, the responsiveness of dopamine increases until the BMI rises to approximately 35 to 40 kg/m², following which a reward deficiency occurs, in severe obesity (28, 30). Brain dopamine neurotransmission is regulated by DAT, which drives reuptake of extracellular dopamine into presynaptic neurons (19). Previously, we used the glucose infusion to reflect food intake, and we have discovered that intravenous glucose loading induced substantial increases of striatal DAT availability by the action of insulin (23). From animal studies, insulin acts on striatal insulin receptors to enhance the surface expression of DAT through the PI3 kinase signalling pathway (31, 32). Therefore, food intake induced insulin signal works on the reward system through the dopamine function (32, 33).

In this study, we investigated the association of DAT availability with overweight/obesity, not with eating behavior. The state of overweight/obesity might be the results of excessive repetition of eating behavior. Therefore, the action of DAT on eating behavior might be different from that of the state of overweight/obesity. DAT is a major target for various pharmacologically active drugs. However, DAT is insensitive to the concentration of synaptic dopamine, as no change of DAT availability was observed after depletion of dopamine or release of dopamine, different from DR (34, 35). Therefore, no significant change of DAT in overweight/obesity may result from insensitivity of DAT to synaptic dopamine concentration, although synaptic dopamine concentration is increased or decreased in overweight/obesity. In addition, DAT may not have a role in the state of overweight/obesity, although it has an important role through the action of insulin in eating behavior.

This study has several limitations. First, a small number of studies were included in this meta-analysis. Therefore, the data from two studies of ¹²³I-FP-CIT could be pooled to analyze the role of DAT in obesity. Second, radiopharmaceuticals, image processing, and data analysis techniques are different across the studies included in this meta-analysis, which might impact DAT availability. However, to adjust the inter-study variability, we adopted DAT ratio, rather than DAT availability. Third, although two authors extracted the BMI and corresponding DAT availability from figures in the studies, the data may be inaccurate.

In conclusion, dopamine plays a main role in the reward system with regard to obesity. Compared to subjects with normal BMI, those of overweight/obesity did not have a different DAT availability.

Funding

None

CONFLICT OF INTEREST

Nothing to declare

AUTHOR CONTRIBUTION

Kyoungjune Pak; study design, write the manuscript, image analysis, statistical analysis Keunyoung Kim; image analysis

In Joo Kim; image analysis, statistical analysis

DATA AVAILABILITY

The datasets generated during the current study are available from the corresponding author on reasonable request.